Information for Healthcare Professionals

Type 1 Diabetes TrialNet is an international consortium dedicated to advancing the science of prevention and early treatment to preserve residual insulin secretion in type 1 diabetes. Researchers in the United States, Canada, United Kingdom, Finland, Italy, Germany, Australia and New Zealand are involved in designing clinical trials in the following research areas:

• Pathway to Prevention Study: This study will enable us to learn more about risk factors associated with the development of type 1 diabetes.
  
  
• Diabetes Prevention Studies: These studies will test therapies that may delay or prevent the onset of type 1 diabetes.
  
  
• Diabetes Intervention Studies: These studies will test therapies to preserve insulin producing cells in people recently diagnosed with type 1 diabetes.

TrialNet is the successor clinical trials network to the Diabetes Prevention Trial-Type 1 (DPT-1) and will provide an infrastructure for the conduct of future clinical trials in type 1 diabetes. Multiple trials will be conducted simultaneously under this structure, which consists of 18 Clinical Centers worldwide with approximately 100 Affiliates participating as collaborating clinical sites.

Physicians can join TrialNet as an Affiliate or Participating Physician. Clinicians involved in the treatment of type 1 diabetes can offer screening to family members of patients with type 1 diabetes and refer those at risk into studies designed to offer close monitoring or into a prevention trial testing interventions designed to interdict the disease process. Physicians can participate in studies, or offer referrals, for patients with newly diagnosed type 1 diabetes. These studies are testing interventions to preserve insulin secretion.